Sudeep Pharma IPO Details
| Detail | Description |
|---|---|
| IPO Date | November 21, 2025, to November 25, 2025 |
| Listing Date | [.] |
| Face Value | ₹ 1 per share |
| Issue Price Band | ₹ 563 to ₹ 593 per share |
| Lot Size | 25 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 1,50,92,750 shares (aggregating up to ₹ 895.00 Cr) |
| Reserved for Market Maker | 16,02,024 shares (aggregating up to ₹ 95.00 Cr) |
| Net Offered to Public | 1,34,90,726 shares of ₹1 (aggregating up to ₹ 800.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE and NSE |
| Share Holding Pre Issue | 11,13,46,602 shares |
| Share Holding Post Issue | 11,29,48,626 shares |
About Sudeep Pharma IPO
The Sudeep Pharma IPO is worth ₹895.00 cr, comprising a fresh issue of 0.16 crore shares aggregating to ₹95.00 crores and an offer for sale of 1.35 crore shares aggregating to ₹800.00 crores. The book-building issue opens for subscription on November 21, 2025, and closes on November 25, 2025.
The IPO allotment is expected to be finalized on November 26, 2025, and the tentative listing date is November 28, 2025. The price band is set at ₹563.00 to ₹593.00 per share. The lot size investment for sNII is 14 lots (350 shares) amounting to ₹2,07,550, and for bNII it is 68 lots (1,700 shares) amounting to ₹10,08,100.
The minimum amount of investment required by a retail investor for the Sudeep Pharma Ltd. IPO is ₹14,825 (25 shares) (based on the upper price). The Sudeep Pharma IPO will list on the BSE and NSE exchanges.ICICI Securities Ltd. is the book-running lead manager, while MUFG Intime India Pvt.Ltd is the registrar of the issue.
Company Background
Headquartered in Vadodara, Gujarat, Sudeep Pharma Limited was incorporated in 1989 as a domestic mineral salts manufacturer and has evolved into a global supplier of pharmaceutical excipients, food-grade minerals and specialty nutrition ingredients.
The company operates six manufacturing facilities with a combined production capacity of 50,000 MT. It specializes in minerals including calcium, iron, magnesium, zinc, potassium and sodium. Its facilities support advanced technologies such as spray drying, granulation, encapsulation and blending.
Operations and Product Range
Sudeep Pharma Ltd. runs six manufacturing facilities with an aggregated capacity of 50,000–70,000+ MT per annum. These sites feature multiple production lines dedicated to spray-dried grades, mineral salts and specialty excipients that meet strict pharmaceutical and food-safety standards.
The product basket includes food-grade minerals, pharmaceutical excipients, specialty nutrition ingredients and value-added forms such as encapsulated minerals, triturates and spray-dried minerals. These are used in solid oral dosage forms, dietary supplements, fortified foods, beverages, infant nutrition and clinical nutrition.
Revenue Channels
The company’s revenue is diversified across pharmaceutical formulations, food and beverage fortification and nutrition/supplements. Mineral excipients and actives are at the core of each segment.
A large part of the company’s sales is export-driven, allowing global market access and reducing geographic dependence. Growth is supported by a portfolio of 200+ SKUs and customized grades developed in collaboration with clients’ R&D teams.
Management and Shareholding
The Sudeep Pharma IPO is promoted by Sujit Jaysukh Bhayani (Chairman & MD), along with Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Pvt. Ltd. and the Bhayani Family Trust.
Pre-IPO, promoters hold 89.37% of the company’s equity through direct and family entity holdings.
Post-issue promoter shareholding is expected to reduce to 76.15% following the OFS and fresh issue.
Sudeep Pharma IPO Objectives
The company aims to invest capital expenditure of ₹75.81 towards the procurement of machinery for the production line located at Nandesari Facility I, and for general corporate purposes.
Conclusion
The Sudeep Pharma IPO, valued at ₹895 crore, opens on November 21, 2025 and closes on November 25, 2025. It features a fresh issue of ₹95 crore and an OFS of ₹800 crore.
The price band is ₹563–₹593 per share with a minimum investment of ₹14,825. ICICI Securities Ltd. is the lead manager, and MUFG Intime India Pvt. Ltd. is the registrar.
Sudeep Pharma Ltd. is a major player in pharmaceutical excipients and specialty nutrition ingredients, with a global presence in 100+ countries. It operates six manufacturing plants, including one in Europe (Ireland), with a total capacity of 50,000 MT.
The promoter group continues to hold a significant stake post-IPO, ensuring stability in management. The IPO is scheduled to be listed on BSE and NSE on November 28, 2025.
Sudeep Pharma IPO Financial Information
Latest Revenue
130.08
₹ Crore
Profit After Tax
31.27
₹ Crore
Net Worth
688.32
₹ Crore
Total Borrowing
135.97
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 30 Jun 2025 | 922.26 | 130.08 | 31.27 | 688.32 | 135.97 | ||||
| 31 Mar 2025 | 717.17 | 511.33 | 138.69 | 497.53 | 135.25 | ||||
| 31 Mar 2024 | 513.87 | 465.38 | 133.15 | 359.07 | 75.03 | ||||
| 31 Mar 2023 | 420.11 | 438.26 | 62.32 | 226.29 | 82.26 | ||||
| Amount in ₹ Crore | |||||||||
Sudeep Pharma Key Performance Indicator
| KPI | Values |
|---|---|
| Debt/Equity | 0.20 |
| RoNW | 27.88% |
| EBITDA Margin | 39.70% |
| Price to Book Value | 12.93 |
| Market Capitalization | ₹6,697.85 Cr. |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 12.46 | 11.07 |
| P/E (x) | 47.61 | 53.55 |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
The company operates in a high-entry-barrier industry.
The company serves more than 100 countries worldwide, including Pfizer, Merck, Danone, and Aurobindo Pharma.
The company operates six well-equipped manufacturing plants compliant with USFDA, WHO-GMP, ISO certifications, Kosher, Halal, and other global standards.
Download regulatory filings
Sudeep Pharma IPO Timeline
| IPO Open Date | November 21, 2025 |
| IPO Close Date | November 25, 2025 |
| Tentative Allotment | November 26, 2025 |
| Initiation of Refunds | November 27, 2025 |
| Credit of Shares to Demat | November 27, 2025 |
| Tentative Listing Date | November 28, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Mon, November 25, 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | 25 | ₹14,825 |
| Individual investors (Retail) (Max) | 13 | 325 | ₹1,92,725 |
| S-HNI (Min) | 14 | 350 | ₹2,07,550 |
| S-HNI (Max) | 67 | 1,675 | ₹9,93,275 |
| B-HNI (Min) | 68 | 1,700 | ₹10,08,100 |